jetcityimage/iStock Editorial through Getty Pictures
- AmerisourceBergen Drug, now often known as Cencora (NYSE:COR) awarded an estimated ~$2B modification extending the third two-year six-month possibility interval of a two-year six-month base contract with three two-year six-month possibility intervals for prime vendor pharmaceutical and pharmaceutical-related merchandise and
